Faron Pharmaceuticals Oy (LON:FARN) Trading Up 16.7% – Here’s What Happened

Shares of Faron Pharmaceuticals Oy (LON:FARN) rose 16.7% during mid-day trading on Wednesday . The stock traded as high as GBX 61.50 and last traded at GBX 59.50. Approximately 97,510 shares traded hands during trading, a decline of 48% from the average daily volume of 186,179 shares. The stock had previously closed at GBX 51.

Faron Pharmaceuticals Oy Stock Performance

The stock has a market capitalization of £66.36 million, a price-to-earnings ratio of -2.15 and a beta of 0.36. The company has a current ratio of 1.89, a quick ratio of 1.09 and a debt-to-equity ratio of -137.93. The stock’s 50 day moving average is GBX 137.20 and its two-hundred day moving average is GBX 170.82.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280. 4.05% of the stock is owned by corporate insiders.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.